148 related articles for article (PubMed ID: 37672559)
1. Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes.
Pant A; Lim M
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2312277120. PubMed ID: 37672559
[No Abstract] [Full Text] [Related]
2. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of the
Makhlin I; Salinas RD; Zhang D; Jacob F; Ming GL; Song H; Saxena D; Dorsey JF; Nasrallah MP; Morrissette JJ; Binder ZA; O'Rourke DM; Desai AS; Brem S; Bagley SJ
CNS Oncol; 2019 Nov; 8(3):CNS43. PubMed ID: 31769726
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
6. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Zhu Y; Shah K
Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.
Lu Z; Zhou L; Killela P; Rasheed AB; Di C; Poe WE; McLendon RE; Bigner DD; Nicchitta C; Yan H
Cancer Res; 2009 Dec; 69(23):9105-11. PubMed ID: 19920201
[TBL] [Abstract][Full Text] [Related]
8. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Eskilsson E; Røsland GV; Solecki G; Wang Q; Harter PN; Graziani G; Verhaak RGW; Winkler F; Bjerkvig R; Miletic H
Neuro Oncol; 2018 May; 20(6):743-752. PubMed ID: 29040782
[TBL] [Abstract][Full Text] [Related]
9. The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme.
Canute GW; Longo SL; Longo JA; Shetler MM; Coyle TE; Winfield JA; Hahn PJ
Neurosurgery; 1998 Mar; 42(3):609-16. PubMed ID: 9526995
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
Parker JJ; Dionne KR; Massarwa R; Klaassen M; Foreman NK; Niswander L; Canoll P; Kleinschmidt-Demasters BK; Waziri A
Neuro Oncol; 2013 Aug; 15(8):1048-57. PubMed ID: 23749785
[TBL] [Abstract][Full Text] [Related]
11.
Wu S; Gao F; Zheng S; Zhang C; Martinez-Ledesma E; Ezhilarasan R; Ding J; Li X; Feng N; Multani A; Sulman EP; Verhaak RG; de Groot JF; Heffernan TP; Yung WKA; Koul D
Clin Cancer Res; 2020 Mar; 26(6):1395-1407. PubMed ID: 31852834
[TBL] [Abstract][Full Text] [Related]
12. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
14. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
15. A novel co-targeting strategy of EGFR/SEC61G for multi-modality fluorescence/MR/photoacoustic imaging of glioblastoma.
Huang Q; Wang K; Wanggou S; Tian J; Li X
Nanomedicine; 2022 Feb; 40():102509. PubMed ID: 34915180
[TBL] [Abstract][Full Text] [Related]
16. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
[TBL] [Abstract][Full Text] [Related]
17. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
18. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
19. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.
Liu F; Mischel PS
Wiley Interdiscip Rev Syst Biol Med; 2018 Jan; 10(1):. PubMed ID: 28892308
[TBL] [Abstract][Full Text] [Related]
20. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]